Sarah Fredriksson, Aqilion CEO

Mer­ck hands Swedish biotech €10M cash to de­vel­op an­ti-in­flam­ma­to­ry drugs

Mer­ck is bet­ting on Aqil­ion’s work on a small mol­e­cule in­hibitor for au­toim­mune and in­flam­ma­to­ry dis­eases, in­clud­ing neu­ro­log­i­cal dis­eases.

Mer­ck is pay­ing €10 mil­lion up­front cash to the Swedish-based biotech in a li­cens­ing deal and re­search col­lab­o­ra­tion to de­vel­op small mol­e­cule in­hibitors of the growth fac­tor-β-ac­ti­vat­ed ki­nase 1 (TAK1) with the po­ten­tial for an­oth­er €950 mil­lion in de­vel­op­ment and com­mer­cial­iza­tion mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.